CTLA-4, associated with the attenuation of T cell activation by preventing CD28 on T cells from binding its co-stimulatory counterparts (CD80 and CD86) on antigen-presenting cells (APCs) (34), demonstrated a modest efficacy for AML in vitro and in vivo upon blocking (4). This evidence concerns the gene CD80 and acute myeloid leukemia.